Clinical Study

A Study Of Long-Acting Cabotegravir Plus Vrc-Hivmab075-00-Ab (Vrc07-523Ls) To Maintain Viral Suppression In Adults Living With Hiv-1

Posted Date: Apr 28, 2020

  • Investigator: Carl Fichtenbaum
  • Specialties:
  • Type of Study: Drug

This is a Phase II, single arm, open-label switch study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS) in adults living with HIV-1 with suppressed plasma viremia. At Step 1 entry, all participants will discontinue their current HIV regimen except for nucleoside reverse transcriptase inhibitors (NRTIs), and initiate oral Cabotegravir (Integrase Inhibitor). Viral load monitoring will occur at entry and week 4 (and also at week 5 if HIV-1 RNA is 50-199 copies/mL at week 4). During Step 1, participants tolerating oral Cabotegravir plus their current two NRTIs with HIV-1 RNA <50 copies/mL at week 4, or HIV-1 RNA of 50-199 copies/mL at week 4 followed by HIV-1 RNA <50 copies/mL at week 5, will register to Step 2 and receive CAB LA every 4 weeks through week R2+44 plus VRC07-523LS every 8 weeks through week R2+40. Participants in Step 1 who are not eligible for Step 2 entry will be switched to a standard of care (SOC) regimen and followed on study every 2 weeks for a total of 4 weeks and then be taken off study.


Persons Living With Hiv That Have A Cd4 Lymphocyte Count More Than 350 Cells Cu Mm And Are Undetectable By Hiv Rna Viral Load Assay (Hiv < 50 Copies/Ml) Who Are Between 53 - 115 Kg In Weight.


Hiv, Cabotegravir, Neutralizing Antibodies To Hiv

For More Information:

Sharon Kohrs

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.